Publications

, A van Dongen-Leunis, AMM Arons, JR Ladestein, PM Hoogerbrugge, CA Uyl‐de Groot (2020). Cost-effectivness of CAR T-cell therapy for pALL. A societal view.. Cost-effectivness of CAR T-cell therapy for pALL. A societal view.

, HM Blommestein, LEM Oosten, FG Calkoen, AC Lankester, JJ Zwaginga, K Le Blanc, A Redondo, F Sánchez‐Guijo, M Algeri, F Locatelli, WE Fibbe, CA Uyl‐de Groot (2018). Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model.. A decision model for aGvHD: second-line treatment.

PDF Project DOI

Frederick Thielen, Nasuh Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen, Isaac Corro Ramos (2018). Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal. Obinutuzumab with Chemotherapy for the First-Line Treatment of Advanced Follicular Lymphoma.

Frederick Thielen, GAPG Van Mastrigt, LT Burgers, WM Bramer, HJM Majoie, SMAA Evers, J Kleijnen (2016). How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Systematic literature reviews of economic evaluations..